Rapid Acting Insulin Market by Product Type (Insulin Lispro, Insulin Aspart, and Insulin Glulisine), Indication (Type 1 Diabetes and Type 2 Diabetes), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2020–2027
- ALL4621468
- 168 Pages
- March 2021
- Medical Devices
Rapid acting insulin are insulin analogs that have the fastest onset of action than other analogues of insulin These types of insulin analogs enter into the bloodstream within few minutes; hence, it is necessary to inject it after before 5 to 10 minutes of food intake. In addition, rapid acting insulin act very quickly, they can lead to an increased chance of hypoglycemia. Some of the rapid acting insulin available in the market include Fiasp, Humalog, NovoRapid, Apidra and others.
The growth of the global rapid acting insulin market is majorly driven by the surge in prevalence of diabetes worldwide, increase in investment in research and development (R&D) for human recombinant insulin is expected to drive the need for insulin used in management of diabetes thereby boosting the growth of the market. Furthermore, sedentary & unhealthy lifestyles increase all causes of mortality, double the risk of diabetes, because of overweight or obesity, an unhealthy diet and physical inactivity, which account for about 80% of the increase in prevalence of diabetes. However, the reluctance in adoption of rapid acting insulin due to the side effect, such as hypoglycemia, may hinder the growth of the industry. Conversely, untapped market and undiagnosed population in developing regions are expected to provide lucrative growth opportunities for the market growth.
The global rapid acting insulin market is segmented on the basis of product type, indication, distribution channel, and region. By product type, the market is segregated into insulin lispro, insulin aspart and insulin glulisine. Depending on indication, it is fragmented into type 1 diabetes and type 2 diabetes. Furthermore, the market is divided on the basis of distribution channel into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global rapid acting insulin market along with the current trends and future estimations to explain the imminent investment pockets.
The report provides a quantitative analysis for the period of 2019–2027 to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the market by components helps to understand various types of instruments used across regions.
Comprehensive analysis of all regions is provided to determine the prevailing opportunities in these regions.
Key market players have been profiled in the report and their strategies have been analyzed thoroughly to understand the competitive outlook of the global market.
Extensive analysis of the market is conducted by closely following key product positioning and monitoring the top contenders within the market framework.
KEY MARKET SEGMENTS
By Product Type
• Insulin Lispro
• Insulin Aspart
• Insulin Glulisine
By Indication
• Type 1 Diabetes
• Type 2 Diabetes
By Distribution Channel
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Providers
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Australia
o Japan
o India
o China
o South Korea
o Rest of Asia-Pacific
o
• LAMEA
o Latin America
o Middle East & Africa
o
KEY MARKET PLAYERS
• ADOCIA SAS
• Biocon Limited
• Eli Lilly and Company
• Gan & Lee Pharmaceuticals
• Geropharm LLC
• Mannkind Corporation
• Novo Nordisk A/S
• Sanofi S.A.
• Wockhadt Ltd.
1.1.Report description
1.1.Key benefits for stakeholders
1.2.Key market segments
1.2.1.List of key players profiled in the report
1.3.Research methodology
1.3.1.Secondary research
1.3.2.Primary research
1.3.3.Analyst tools and models
1.3.4.Primary research
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies, 2019
3.3.Top player positioning, 2019
3.4.Porter’s five forces analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Sedentary and unhealthy lifestyle
3.5.1.2.Increased availability of continuous glucose monitoring
3.5.1.3.Increasing investment in research and development (R&D) for human recombinant insulin
3.5.1.4.Increase in government expenditure on healthcare
3.5.2.Restraints
3.5.2.1.Adverse effects associated with the use of rapid acting insulin
3.5.3.Opportunities
3.5.3.1.Untapped opportunities and undiagnosed population in developing regions
3.5.4.Impact analysis
3.6.COVID-19 Impact Analysis On Rapid Acting Insulin Market
CHAPTER 4:RAPID ACTING INSULIN MARKET, BY PRODUCT TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Lispro Insulin
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Aspart Insulin
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Glulisine Insulin
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
CHAPTER 5:RAPID ACTING INSULIN MARKET, BY INDICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Type 1 Diabetes
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Type 2 Diabetes
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
CHAPTER 6:RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospital Pharmacies
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Drug Stores & retail pharmacies
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.4.Online providers
6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country
CHAPTER 7:RAPID ACTING INSULIN MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America rapid acting insulin market, by country
7.2.2.1.U.S.
7.2.2.1.1.Market size and forecast, by product
7.2.2.1.2.Market size and forecast, by indication
7.2.2.1.3.Market size and forecast, by distribution channel
7.2.2.2.Canada
7.2.2.2.1.Market size and forecast, by product
7.2.2.2.2.Market size and forecast, by indication
7.2.2.2.3.Market size and forecast, by distribution channel
7.2.2.3.Mexico
7.2.2.3.1.Market size and forecast, by type
7.2.2.3.2.Market size and forecast, by indication
7.2.2.3.3.Market size and forecast, by distribution channel
7.2.3.North America market size and forecast, type
7.2.4.North America market size and forecast, indication
7.2.5.North America market size and forecast, by distribution channel
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe rapid acting insulin market, by country
7.3.2.1.Germany
7.3.2.1.1.Market size and forecast, by type
7.3.2.1.2.Market size and forecast, by indication
7.3.2.1.3.Market size and forecast, by distribution channel
7.3.2.2.UK
7.3.2.2.1.Market size and forecast, by type
7.3.2.2.2.Market size and forecast, by indication
7.3.2.2.3.Market size and forecast, by distribution channel
7.3.2.3.France
7.3.2.3.1.Market size and forecast, by type
7.3.2.3.2.Market size and forecast, by indication
7.3.2.3.3.Market size and forecast, by distribution channel
7.3.2.4.Italy
7.3.2.4.1.Market size and forecast, by type
7.3.2.4.2.Market size and forecast, by indication
7.3.2.4.3.Market size and forecast, by distribution channel
7.3.2.5.Spain
7.3.2.5.1.Market size and forecast, by type
7.3.2.5.2.Market size and forecast, by indication
7.3.2.5.3.Market size and forecast, by distribution channel
7.3.2.6.Rest of Europe
7.3.2.6.1.Market size and forecast, by type
7.3.2.6.2.Market size and forecast, by indication
7.3.2.6.3.Market size and forecast, by distribution channel
7.3.3.Europe market size and forecast, type
7.3.4.Europe market size and forecast, indication
7.3.5.Europe market size and forecast, by distribution channel
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific Rapid acting insulin market, by country
7.4.2.1.China
7.4.2.1.1.Market size and forecast, by type
7.4.2.1.2.Market size and forecast, by indication
7.4.2.1.3.Market size and forecast, by distribution channel
7.4.2.2.Japan
7.4.2.2.1.Market size and forecast, by type
7.4.2.2.2.Market size and forecast, by indication
7.4.2.2.3.Market size and forecast, by distribution channel
7.4.2.3.Australia
7.4.2.3.1.Market size and forecast, by type
7.4.2.3.2.Market size and forecast, by indication
7.4.2.3.3.Market size and forecast, by distribution channel
7.4.2.4.India
7.4.2.4.1.Market size and forecast, by type
7.4.2.4.2.Market size and forecast, by indication
7.4.2.4.3.Market size and forecast, by distribution channel
7.4.2.5.Rest of Asia-Pacific
7.4.2.5.1.Market size and forecast, by type
7.4.2.5.2.Market size and forecast, by indication
7.4.2.5.3.Market size and forecast, by distribution channel
7.4.3.Asia-Pacific market size and forecast, by type
7.4.4.Asia-Pacific market size and forecast, by indication
7.4.5.Asia-Pacific market size and forecast, by distribution channel
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA rapid acting insulin market, by country
7.5.2.1.Latin America
7.5.2.1.1.Market size and forecast, by type
7.5.2.1.2.Market size and forecast, by indication
7.5.2.1.3.Market size and forecast, by distribution channel
7.5.2.2.Middle East & Africa
7.5.2.2.1.Market size and forecast, by type
7.5.2.2.2.Market size and forecast, by indication
7.5.2.2.3.Market size and forecast, by distribution channel
7.5.3.LAMEA market size and forecast, by type
7.5.4.LAMEA market size and forecast, by indication
7.5.5.LAMEA market size and forecast, by distribution channel
CHAPTER 8:COMPANY PROFILES
8.1.ADOCIA SAS
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.2.Biocon Limited
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segment
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.Eli Lilly And Company
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segment
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.Gan & Lee Pharmaceuticals
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Key strategic moves and developments
8.5.Geropharm LLC
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Key strategic moves and developments
8.6.Mannkind Corporation
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segment
8.6.4.Product portfolio
8.6.5.Business performance
8.7.Novo Nordisk A/S
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segment
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.Sanofi S.A.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segment
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.Wockhadt Ltd.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segment
8.9.4.Product portfolio
8.9.5.Business performance
TABLE 01.RAPID ACTING INSULIN MARKET, BY PRODUCT TYPE, 2019–2027 ($MILLION)
TABLE 02.RAPID ACTING INSULIN MARKET FOR LISPRO INSULIN, BY REGION, 2019–2027 ($MILLION)
TABLE 03.RAPID ACTING INSULIN MARKET FOR ASPART INSULIN, BY REGION, 2019–2027 ($MILLION)
TABLE 04.RAPID ACTING INSULIN MARKET FOR GLULISINE INSULIN, BY REGION, 2019–2027 ($MILLION)
TABLE 05.RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 06.RAPID ACTING INSULIN MARKET FOR TYPE 1 DIABETES, BY REGION, 2019–2027 ($MILLION)
TABLE 07.RAPID ACTING INSULIN MARKET FOR TYPE 2 DIABETES, BY REGION, 2019–2027 ($MILLION)
TABLE 08.RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 09.RAPID ACTING INSULIN MARKET FOR HOSPITAL PHARMACY, BY REGION, 2019–2027 ($MILLION)
TABLE 10.RAPID ACTING INSULIN MARKET FOR DRUG STORE & RETAIL PHARMACY, BY REGION, 2019–2027 ($MILLION)
TABLE 11.RAPID ACTING INSULIN MARKET FOR ONLINE PROVIDERS, BY REGION, 2019–2027 ($MILLION)
TABLE 12.RAPID ACTING INSULIN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 13.NORTH AMERICA RAPID ACTING INSULIN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 14.U.S. RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 15.U.S. RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 16.U.S. RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 17.CANADA RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 18.CANADA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 19.CANADA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 20.MEXICO RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 21.MEXICO RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 22.MEXICO RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 23.NORTH AMERICA RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 24.NORTH AMERICA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 25.NORTH AMERICA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 26.EUROPE RAPID ACTING INSULIN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 27.GERMANY RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 28.GERMANY RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 29.GERMANY RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 30.UK RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 31.UK RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 32.UK RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 33.FRANCE RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 34.FRANCE RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 35.FRANCE RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 36.ITALY RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 37.ITALY RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 38.ITALY RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 39.SPAIN RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 40.SPAIN RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 41.SPAIN RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 42.REST OF EUROPE RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 43.REST OF EUROPE RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 44.REST OF EUROPE RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 45.EUROPE RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 46.EUROPE RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 47.EUROPE RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 48.ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 49.CHINA RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 50.CHINA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 51.CHINA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 52.JAPAN RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 53.JAPAN RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 54.JAPAN RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 55.AUSTRALIA RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 56.AUSTRALIA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 57.AUSTRALIA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 58.INDIA RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 59.INDIA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 60.INDIA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 61.REST OF ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 62.REST OF ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 63.REST OF ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 64.ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 65.ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 66.ASIA-PACIFIC RAPID ACTING INSULIN MARKET, BY DISTRIBUTION MARKET, 2019–2027 ($MILLION)
TABLE 67.LAMEA RAPID ACTING INSULIN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 68.LATIN AMERICA RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 69.LATIN AMERICA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 70.LATIN AMERICA RAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 71.MIDDLE EAST & AFRICA RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 72.MIDDLE EAST & AFRICARAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 73.MIDDLE EAST & AFRICARAPID ACTING INSULIN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 74.LAMEA RAPID ACTING INSULIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 75.LAMEA RAPID ACTING INSULIN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 76.LAMEA RAPID ACTING INSULIN MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 01.ADOCIA: COMPANY SNAPSHOT
TABLE 02.ADOCIA: OPERATING SEGMENTS
TABLE 03.ADOCIA: PRODUCT PORTFOLIO
TABLE 04.BIOCON: COMPANY SNAPSHOT
TABLE 05.BIOCON: OPERATING SEGMENTS
TABLE 06.BIOCON: PRODUCT PORTFOLIO
TABLE 07.ELI LILLY: COMPANY SNAPSHOT
TABLE 08.ELI LILLY: OPERATING SEGMENTS
TABLE 09.ELI LILLY: PRODUCT PORTFOLIO
TABLE 10.GAN&LEE: COMPANY SNAPSHOT
TABLE 11.GAN&LEE: PRODUCT PORTFOLIO
TABLE 12.GEROPHARM: COMPANY SNAPSHOT
TABLE 13.GEROPHARM: OPERATING SEGMENTS
TABLE 14.GEROPHARM: PRODUCT PORTFOLIO
TABLE 15.MANNKIND: COMPANY SNAPSHOT
TABLE 16.MANNKIND: OPERATING SEGMENTS
TABLE 17.MANNKIND: PRODUCT PORTFOLIO
TABLE 18.NOVO NORDISK: COMPANY SNAPSHOT
TABLE 19.NOVO NORDISK: OPERATING SEGMENTS
TABLE 20.NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 21.SANOFI: COMPANY SNAPSHOT
TABLE 22.SANOFI: PRODUCT PORTFOLIO
TABLE 23.WOCKHARDT: COMPANY SNAPSHOT
TABLE 24.WOCKHARDT: OPERATING SEGMENTS
TABLE 25.WOCKHARDT: PRODUCT PORTFOLIO
Similar Reports
Medical implants are permanent devices such as pacemakers or temporary devices such as fracture plates which are removed once their function is completed. These implants are made up of bone, tissue, skin, ceramics, metals, plastics, and other natural materials...
- Publish Date: August 21, 2016
- $5370
Ostomy is a surgery wherein an artificial opening, known as stoma, is created from the colon in the human body to eliminate body wastes such as urine, mucus, and stools, which are collected in artificial bags called ostomy drainage bags. These plastic/rub...
- Publish Date: December 1, 2016
- $5370
Laparoscopy is a minimally invasive procedure used to examine organs inside the abdomen or pelvic cavities by inserting a laparoscope through a small incision in the abdomen. A laparoscope comprises a long, thin tube with high-intensity light, and high-re...
- Publish Date: April 24, 2017
- $5370
